Auro Laboratories Ltd
Auro Laboratories Ltd Live Price Chart
Auro Laboratories Ltd Technicals
| 20 Day | ₹ 231.085 |
| 50 Day | ₹ 233.310 |
| 100 Day | ₹ 235.303 |
| 200 Day | ₹ 236.326 |
| 20 Day | ₹ 225.948 |
| 50 Day | ₹ 240.100 |
| 100 Day | ₹ 230.772 |
| 200 Day | ₹ 244.447 |
Auro Laboratories Ltd Performance
| Previous Close | ₹ 253.95 |
| High | ₹ 266 |
| Volume | 29713 |
| 52W Range | ₹ 159 - ₹ 303 |
| Open | ₹ 254.9 |
| Low | ₹ 243.75 |
| Market Cap | ₹ 160 Cr |
Auro Laboratories Ltd Fundamentals
| ROCE | 4.199 |
| P/E Ratio | 156.540 |
| P/B Ratio | 3.780 |
| Industry P/E | 3.780 |
| Debt to Equity | 39.828 |
| ROE | 2.422 |
| EPS | 1.690 |
| Dividend Yield | 0.000 |
| Book Value | 69.921 |
| Face Value | 10.000 |
Auro Laboratories Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 20.0544 | 55.1391 | 53.8355 | 51.9583 | 55.0097106 |
| Total Expenses | 18.1736 | 44.7935 | 50.3898 | 48.0844 | 44.5042829 |
| Profit After Tax | 1.8387 | 7.7921 | 2.442 | 2.8446 | 7.1795759 |
Auro Laboratories Ltd Shareholding Pattern
| Promoter Holdings | 52.177 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.006 % |
| Retail | 36.257 % |
| Others - | 11.561 % |
About Auro Laboratories Ltd
History of Auro Laboratories Ltd
Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API). Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes. The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra. The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards. Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments. Currently, it manufacture Metformin Hydrochloride and Glibenclamide and are on the anvil of introducing others within this segment. Additionally, it also undertake Toll/Custom Manufacturing for API's and Intermediates on contract basis. The manufacturing facility operates are per cGMP norms and has an installed capacity in excess of 500 Tonnes per annum. Auro laboratories has made its presence felt in international markets with a bulk of it production being exported to South East Asia, Middle East and several European Countries. Some of the countries the company exports to are Egypt, Germany, Malaysia, Singapore, South A ...
